Publication details
Current pharmacotherapy of depression - focused on multimodal/multifunctional antidepressants
| Authors | |
|---|---|
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | EXPERT OPINION ON PHARMACOTHERAPY |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.tandfonline.com/doi/full/10.1080/14656566.2016.1219340?scroll=top&needAccess=true |
| Doi | http://dx.doi.org/10.1080/14656566.2016.1219340 |
| Field | Pharmacology and pharmaceutical chemistry |
| Keywords | Depressive disorder; pharmacoresistance; multimodal; multifunctional antidepressants; pharmacogenomic tests |
| Description | Major depressive disorder (MDD) is a widespread disease, with a lifetime prevalence of 15% and an annual incidence of approximately 7%. It is associated with significant costs in quality of life, loss of work productivity, and a high risk of mortality. It is predicted to become the leading cause of disability in Western countries by 2030. |
| Related projects: |